Literature DB >> 12114697

p53/MDM2 Pathway Aberrations in Parathyroid Tumors: p21(WAF-1) and MDM2 Are Frequently Overexpressed in Parathyroid Adenomas.

Begona Arribas1, Eva Cristobal, Jose A. Alcazar, Juan Tardio, Juan C. Matinez-Montero, Jose R. Polo, Rafael Carrion, Laura Gil, Marta Azanedo, Jose M. Rojas, Javier Menarguez.   

Abstract

Parathyroid adenomas (PTAs) are the main cause of primary hyperparathyroidism. Cell cycle regulation in normal parathyroid tissue (NPT) and PTA remains largely unknown. We have systematically explored several components involved in the p53/MDM2/p19(ARF) pathway in PTA and compared the results were with NPT. Forty-six PTA and 12 NPT were immunostained with anti-p21(WAF-1), MDM2, p53, and p27(KP1) antibodies. The slides were processed by cytometry and the results were statistically analyzed using nonparametric methods (Mann-Whitney test). p2l(WAF-1) and MDM2 expression were significantly higher in PTA compared with NPT (p < 0.05). The opposite results were found for p27(KIP1) (p< 0.05). Occasional p53 staining was found in some PTA, albeit no significant difference was found in comparison with NPT. In conclusion, MDM2 and p2l(WAF-1) are the proteins more overexpressed in PTA. These findings are surprising taking into account the benign nature of PTA, making them suitable candidates for further molecular analysis.

Entities:  

Year:  2000        PMID: 12114697     DOI: 10.1385/ep:11:3:251

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  40 in total

1.  p14ARF links the tumour suppressors RB and p53.

Authors:  S Bates; A C Phillips; P A Clark; F Stott; G Peters; R L Ludwig; K H Vousden
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

2.  Assessment of proliferative activity of glandular cells in hyperfunctioning parathyroid gland using flow cytometric and immunohistochemical methods.

Authors:  P Xiao-Lin; N Koide; S Kobayashi; M Kobayashi; A Sugenoya; F Iida; T Katsuyama; N Usuda; T Nagata
Journal:  World J Surg       Date:  1996 Mar-Apr       Impact factor: 3.352

3.  Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.

Authors:  E D Hsi; L R Zukerberg; W I Yang; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

Review 4.  Genetic alterations in primary and secondary hyperparathyroidism.

Authors:  L Shan; Y Nakamura; M Nakamura; T Yokoi; K Kakudo
Journal:  Pathol Int       Date:  1998-08       Impact factor: 2.534

5.  The basal rate of cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism.

Authors:  Q Wang; S Palnitkar; A M Parfitt
Journal:  Clin Endocrinol (Oxf)       Date:  1997-03       Impact factor: 3.478

6.  The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.

Authors:  M P Vargas; H I Vargas; D E Kleiner; M J Merino
Journal:  Mod Pathol       Date:  1997-01       Impact factor: 7.842

Review 7.  Frequent loss of chromosome arm 1p DNA in parathyroid adenomas.

Authors:  V L Cryns; S M Yi; H Tahara; R D Gaz; A Arnold
Journal:  Genes Chromosomes Cancer       Date:  1995-05       Impact factor: 5.006

8.  A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas.

Authors:  M J Kayath; L C Martin; J G Vieira; L M Roman; V Nosé-Alberti
Journal:  Eur J Endocrinol       Date:  1998-07       Impact factor: 6.664

9.  p53 abnormalities in human parathyroid carcinoma.

Authors:  V L Cryns; M P Rubio; A D Thor; D N Louis; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

10.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Authors:  K Yoshimoto; H Iwahana; A Fukuda; T Sano; S Saito; M Itakura
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

View more
  2 in total

1.  Non-functioning parathyroid cystic tumour: malignant or not? Report of a case.

Authors:  G Cocorullo; G Scerrino; G Melfa; C Raspanti; G Rotolo; V Mannino; P Richiusa; D Cabibi; A G Giannone; C Porrello; G Gulotta
Journal:  G Chir       Date:  2017 Sep-Oct

Review 2.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.